Clinical Trial

Platelet Rich Plasma in the Prevention of Adhesion Reformation

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated March 11, 2025 (before its estimated April 11, 2025 completion). Its status may not reflect the trial's current state.
Summary
Asherman syndrome, which occurs after trauma to the basalis layer of the endometrium. It seems that the role of postoperative platelet rich plasma（PRP）therapy in the prevention of recurrence of IUA is still controversial. To investigate if PRP therapy can prevent adhesion reformation after adhesiolysis. After the completion of hysteroscopic adhesiolysis, recruited patients will be randomized to one of the two treatment groups by computer-generated numbers: having PRP after hysteroscopic adhesiolysis; and the control group without PRP treatment. A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-19; most recent amendment 2025-03-10.
Trial Details
NCT Number NCT06608407
Lead Sponsor Fu Xing Hospital, Capital Medical University
Conditions Intrauterine Adhesion, Asherman Syndrome
Enrollment 46 participants
Start Date 2023-10-10
Primary Completion 2025-04-11 (estimated)
Study Completion 2025-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-11